Oncology and Hematology - Global Oncology Academy

449-464 of 663

MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 credits 10 episodes
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 credits 10 episodes
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
Nadia Harbeck, MD, PhD
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Treatment Intensification in HR+/HER2- EBC: Who and When?
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Interprofessional Coordination of Adverse Event Management
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
Nadia Harbeck, MD, PhD
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Nadia Harbeck, MD, PhD
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Maximizing Adherence and Persistence via Patient Engagement
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
Hope S. Rugo, MD, FASCO; Nadia Harbeck, MD, PhD
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
Project Oncology®
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
Betsy O'Donnell, MD
- Betsy O'Donnell, MD
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Project Oncology®
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Betsy O'Donnell, MD
- Betsy O'Donnell, MD
Risk Stratification Models for Precursor Diseases in Multiple Myeloma
Risk Stratification Models for Precursor Diseases in Multiple Myeloma
Project Oncology®
Risk Stratification Models for Precursor Diseases in Multiple Myeloma
Betsy O'Donnell, MD
- Betsy O'Donnell, MD
Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
Shubham Pant, MD, MBBS; Ritu Salani, MD, MBA
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Shubham Pant, MD, MBBS
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
Shubham Pant, MD, MBBS; Ritu Salani, MD, MBA
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes

29/11